BioStock: Follicum’s CEO comments on directed share issue of SEK 37 million

Last week, biotech company Follicum announced a directed share issue of SEK 36.6 million to a number of selected investors. The funds will be used to bring the ongoing phase II trial in hair loss across the finish line and advance the preclinical program for the diabetes project. BioStock was able to reach CEO Jan Alenfall on All Saints’ Day weekend for further comments on the capital raise and what it means for the company.

Read the full interview with Follicum's CEO Jan Alenfall at biostock.se:

https://www.biostock.se/en/follicums-ceo-comments-on-directed-share-issue-of-sek-37-million/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se